Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia
- Farhad Ravandi(corresponding author),
- Ellen K. Ritchie,
- Hamid Sayar,
- Jeffrey E. Lancet,
- Michael D. Craig,
- Norbert Vey
- University of Texas MD Anderson Cancer Center,
- Cornell University,
- Indiana University-Purdue University Indianapolis,
- University of South Florida,
- West Virginia University,
- Aix-Marseille Université
Scholary Output:
Contribution to journal
Letter
Peer-review
Open access
Publication Information
Output type
Scholary Output:
Contribution to journal
Letter
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages e514-e518Journal (Volume, Issue Number)
Haematologica (Volume 103, Issue 11)Publication milestones
- Published - 10/31/2018
Publication status
Published - 10/31/2018
ISSN
0390-6078Publication IDs
- Scopus: 85055851886
- PubMed: 29794146
- ORCID: /0000-0002-8636-1071/work/68887808
Publication metrics
Metrics
Fractional count
1
Fractional count
0.04
Fractional count
23
Fractional count
0.96
Fractional count
1
Fractional count
1
SciVal
FWCI
1.21
SciVal
Author count
24
SciVal
citations
5
SciVal
Paper percentile
67
PlumX, opens in new tab
Captures
23
Citation count
13
Funding Details
1University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Weill Cornell Medical Center, New York, NY, USA; 3Indiana University Simon Cancer Center, Indianapolis, IN, USA; 4Moffitt Cancer Center, Tampa, FL, USA; 5West Virginia University, Morgantown, WV, USA; 6Institut Paoli-Calmettes and Aix-Marseille University, Marseille, France; 7Vanderbilt-Ingram Cancer Center, Nashville, TN, USA; 8David Geffen School of Medicine at University of California, Los Angeles, CA, USA; 9Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux, France; 10University Hospital Schleswig-Holstein, Kiel, Germany; 11Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse III, Centre Hospitalier Universitaire de Toulouse, France; 12Memorial Sloan-Kettering Cancer Center, New York, NY, USA;13IRCCS AOU San Martino-IST, Genova, Italy; 14Kaposi Mor Teaching Hospital, Kaposvar, Hungary; 15Universitätsklinikum Münster, Germany; 16Sunesis Pharmaceuticals, Inc., South San Francisco, CA, USA and 17Medical University of South Carolina, Charleston, SC, USA #Current address: Klinikum Leverkusen, Germany Funding: this study was funded by Sunesis Pharmaceuticals Inc. (South San Francisco, CA, USA). Medical writing assistance was provided by Rebecca D. Miles, PhD, of MedVal Scientific Information Services, LLC (Princeton, NJ, USA) and Janis Leonoudakis, PhD of LeoGraphy, LLC (Pleasanton, CA, USA), and was funded by Sunesis Pharmaceuticals. Correspondence: [email protected] doi:10.3324/haematol.2018.191361 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.
FundersFunding number
10University Hospital Schleswig-Holstein
-11Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse III
-17Medical University of South Carolina
-5West Virginia University
-7Vanderbilt-Ingram Cancer Center
-9Université de Bordeaux
-AOU San Martino-IST
-NCI
P30CA016672
AMU
-Sunesis Pharmaceuticals
-Centre Hospitalier Universitaire de Toulouse
-CHU de Bordeaux
-